Replies to post #50894 on Biotech Values

[DewDiligence]

> “Liver toxicity is one of the worst problems you can have in drug development,” said Jason Kolbert, an analyst at Susquehanna Financial Group.<

Especially when the drug in question is treating a liver disease.

[DewDiligence]

HCV scorecard: I forgot about ACH-806.
Here’s an updated scorecard:

Programs killed during 2007
HCV-796* ( WYE / VPHM )
NM283 ( NVS / IDIX )
ACH-806 ( GILD / ACHN )
Actilon ( COLY )
ANA975 ( ANDS )
XTL-2125 ( XTLB )
AVI-4055 ( AVII )

Programs on ‘life support’ (IMO)
R1626 ( Roche )
Celgosivir ( Migenix )
Bavituximab ( PPHM )

*HCV-796 is officially still viable, but few informed observers believe it is not dead.